Insider Transactions in Q1 2021 at Zymeworks Inc. (ZYME)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Kathryn O'Driscoll Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
837
+12.54%
|
$28,458
$34.24 P/Share
|
|
Mar 15
2021
|
Kathryn O'Driscoll Chief People Officer |
SELL
Open market or private sale
|
Direct |
786
-13.58%
|
$26,724
$34.72 P/Share
|
|
Mar 10
2021
|
Neil A Klompas Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,425
-11.98%
|
$48,450
$34.95 P/Share
|
|
Mar 10
2021
|
Neil A Klompas Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+17.37%
|
-
|
|
Mar 10
2021
|
Diana Hausman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,048
-16.31%
|
$35,632
$34.95 P/Share
|
|
Mar 10
2021
|
Diana Hausman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+28.01%
|
-
|
|
Mar 10
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,392
-1.66%
|
$149,328
$34.95 P/Share
|
|
Mar 10
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,708
+2.83%
|
-
|
|
Mar 10
2021
|
Anthony J. Polverino Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,048
-3.27%
|
$35,632
$34.95 P/Share
|
|
Mar 10
2021
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.24%
|
-
|
|
Mar 10
2021
|
Kathryn O'Driscoll Chief People Officer |
SELL
Open market or private sale
|
Direct |
568
-8.94%
|
$19,312
$34.95 P/Share
|
|
Mar 10
2021
|
Kathryn O'Driscoll Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,354
+17.56%
|
-
|
|
Feb 12
2021
|
Kathryn O'Driscoll Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,083
+29.4%
|
$70,822
$34.24 P/Share
|
|
Jan 08
2021
|
Neil A Klompas Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
284
+2.93%
|
$8,520
$30.92 P/Share
|
|
Jan 07
2021
|
Diana Hausman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
207
+5.01%
|
$6,210
$30.92 P/Share
|
|
Jan 07
2021
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48
+0.16%
|
$1,440
$30.92 P/Share
|